EXEL Latest Press Releases

-- October 15, 2026 --

Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026 Business Wire 4:05 PM

-- October 12, 2026 --

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm PRNewswire 8:35 PM

-- September 1, 2026 --

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September Business Wire 4:05 PM

-- August 31, 2026 --

Exelixis Announces Update on Patent Litigation Trial Appeal with MSN Laboratories Business Wire 2:30 PM

-- August 19, 2026 --

Kuehn Law Encourages Investors of EXELIXIS, Inc. to Contact Law Firm PRNewswire 7:53 PM

-- August 17, 2026 --

Exelixis (EXEL) Securities Investigation Notice - Levi & Korsinsky PRNewswire 10:09 AM

-- August 16, 2026 --

EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with SBS Law Business Wire 6:24 PM

-- August 13, 2026 --

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Exelixis (EXEL) Globe Newswire 10:13 AM

-- August 12, 2026 --

EXEL Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Exelixis (EXEL) Business Wire 10:21 AM

-- August 11, 2026 --

EXEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Exelixis PRNewswire 10:07 AM

-- August 10, 2026 --

Exelixis Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Exelixis (EXEL) PRNewswire 6:19 PM

-- August 5, 2026 --

Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update Business Wire 4:05 PM

-- July 22, 2026 --

Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026 Business Wire 4:30 PM

-- June 22, 2026 --

Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer Business Wire 8:00 AM

-- May 30, 2026 --

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026 Business Wire 10:00 AM

-- May 27, 2026 --

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June Business Wire 4:05 PM

-- May 21, 2026 --

Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types Business Wire 5:00 PM

Market Data Delayed 15 Minutes